Halozyme Therapeutics Inc (HALO)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Also measured against its sector ETF (XBI).
Our last 30 days of resolved calls came true 18% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+41% over the past year+3
- QualityRevenue growing 41% y/y+10
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst is earnings, specifically a Q3 report with in-line results and raised guidance that nonetheless disappointed relative to consensus expectations. Given the negative after-hours reaction to an otherwise solid quarter, the probability of near-term continuation in the direction of the initial move is moderate (~50-60%), as post-earnings drift tends to fade when the reaction reflects positioning rather than fundamentals. Informational only — not financial advice.
- Halozyme Stock Jumps On Strong Earnings But Guidance Reset Raises QuestionsYahoo · 2026-11-06
- Halozyme (HALO) Q3 2026 Earnings Call TranscriptYahoo · 2026-11-06
- Halozyme Therapeutics Inc (HALO) (Q3 2026) Earnings Call Highlights: Record Revenue, Raised ...Yahoo · 2026-11-06
- What Halozyme Therapeutics (HALO) Said on Its Q3 Earnings CallYahoo · 2026-11-06
- Halozyme Therapeutics (NASDAQ:HALO) Q3 In Line, Guidance Midpoint Below Consensus, Shares Fall After HoursChartMill · 2026-11-05
Any AI summary is an interpretation of public news, not advice or a price target.